Immunological analysis of Phase IIb trial with Diamyd[®] show differences between genetically defined patient groups

The first immunological results from DIAGNODE-2 show that the the immune response differs significantly between genetically defined patient groups for several immunological parameters following treatment with the diabetes vaccine Diamyd[® ] (GAD-alum). The results are in line with the earlier observed difference in clinical response (announced in September 2020) between individuals positive or negative for HLA type DR3-DQ2. DIAGNODE-2 is a placebo-controlled Phase IIb trial, where Diamyd[®] was injected directly into a lymph node in individuals recently diagnosed with type 1 diabetes.The